Page 113 - book
P. 113

Temad Co.

            IRANIAN PHARMACEUTICAL COMPANIES DIRECTORY




                 Founded:                    1997

                 HQ Office:                  28th km Karaj Makhsous Road - Tehran – Iran

                                             1) 28th km Karaj Makhsous Road - Tehran – Iran
                                             Postal code: 3164816478
                 Plant Location:
                                             2) Next to Tabarok Company – Khajeh Abaselt Cross – 3rd km Fariman Road, Mash-
                                             had, Iran

                 Capital:                    The capital of Temad Co. is about Rial 715000000000

                                             Tamin Pharmaceutical Investment Company
                 Major Shareholder:          Iran Insurance Joint Stock Company
                                             others

                                             As a company with knowledge-based products and with a conscious attitude and
                                             in line with its long-term goals, Temad Company has selected 567 personnel from
                 Employees:                  experienced, committed and responsible, and its scientific staff consists of chem-
                                             ists, chemical engineers and specialized and committed pharmacists and other
                                             disciplines.


                 Company Profile:
                 Temad Co, (Active Pharmaceutical Ingredients), is one of the companies of Tamin Pharmaceutical Investment Com-
                 pany (TPICO) from SSIC SHASTA Group. Temad is one of the largest producers of APIs in Iran and innovative manufac-
                 turer of Narcotics and Non-narcotics in two main categories of Active Pharmaceutical Ingredients (API) and semi-fin-
                 ished (pellets and DC grade) products in the Middle East. In order to expand business by considering the export
                 markets, Temad started planning to produce finished dosage products, such as Syrup, Tablets and Capsule from 2017
                 to achieve the most Narcotics and Non-narcotics market share to supply to domestic pharmaceutical companies.


                 Production Lines:
                 At present, the company has 23 production lines and more than 115 kinds of pharmaceutical products including
                 narcotics and general API’s in different forms such as DC grade API, pellets and non-sterile injectable grade.  All the
                 products are manufactured under the latest pharmacopeia.

                 Certificates:
                 Received ISO 9001:2015 Quality Management System Certificate
                 Received ISO 45001:2018 Certificate for Occupational Health and Safety Management
                 Received ISO 14001:2015 Certificate of Environmental Management
                 Received ISO 10015:2019 Certificate of Quality Management

                 Target Countries for Exports:
                 Asia: Bangladesh, China, Hong Kong, India, Japan, Kazakhstan, Malaysia, Pakistan, South Korea, Syria, Singapore,
                 Taiwan,  Thailand,  Uzbekistan,  Vietnam,  Georgia
                 Europe: Belarus, Belgium, Czech Republic, Denmark, Germany, Netherland, Russia, Switzerland, Turkey, United King-
                 dom
                 Africa: Algeria, Congo, Egypt, Nigeria, South Africa, Uganda, Zimbabwe, Zambia, Ghana , Ivory Coast , Kenya
                 South America: Costa Rica, Chile, Colombia, Guatemala, Venezuela, Brazil, Peru
                 North America: North America, Canada
                 Oceania: New Zealand

                 Premier Partners :
                 Temad Co, supplies its products to all around of Iran as a domestic market and also exports 23 products to 48 coun-
          112    tries in 5 continents, therefore having effective presence as one of the international competitors, has significant role
                 in supplying pharmaceutical materials and narcotics in the global markets
   108   109   110   111   112   113   114   115   116   117   118